JP4465195B2 - 新規化合物 - Google Patents

新規化合物 Download PDF

Info

Publication number
JP4465195B2
JP4465195B2 JP2003580326A JP2003580326A JP4465195B2 JP 4465195 B2 JP4465195 B2 JP 4465195B2 JP 2003580326 A JP2003580326 A JP 2003580326A JP 2003580326 A JP2003580326 A JP 2003580326A JP 4465195 B2 JP4465195 B2 JP 4465195B2
Authority
JP
Japan
Prior art keywords
methyl
amino
morpholinyl
carbonyl
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003580326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005526815A (ja
JP2005526815A5 (enExample
Inventor
アンクリフ，レーチェル，アン
クック，カロライン，メアリー
エルドレッド，コリン，デーヴィッド
ゴア，ポール，マーティン
ハリソン，リー，アンドリュー
ヘイズ，マーティン，アリスター
ホッジソン，サイモン，ティーンバイ
ジャッド，ダンカン，ブルース
キーリング，スザンヌ，エレーヌ
ルウェル，シャオ，キン
ミルズ，ゲイル
ロバートソン，グレアム，マイケル
スワンソン，スティーブン
ウォーカー，アンドリュー，ジョン
ウィルキンソン，マーク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005526815A publication Critical patent/JP2005526815A/ja
Publication of JP2005526815A5 publication Critical patent/JP2005526815A5/ja
Application granted granted Critical
Publication of JP4465195B2 publication Critical patent/JP4465195B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2003580326A 2002-03-28 2003-03-27 新規化合物 Expired - Lifetime JP4465195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds
PCT/EP2003/003335 WO2003082861A2 (en) 2002-03-28 2003-03-27 Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2005526815A JP2005526815A (ja) 2005-09-08
JP2005526815A5 JP2005526815A5 (enExample) 2006-05-18
JP4465195B2 true JP4465195B2 (ja) 2010-05-19

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003580326A Expired - Lifetime JP4465195B2 (ja) 2002-03-28 2003-03-27 新規化合物

Country Status (23)

Country Link
US (1) US7622464B2 (enExample)
EP (1) EP1487828B1 (enExample)
JP (1) JP4465195B2 (enExample)
KR (1) KR20040093488A (enExample)
CN (1) CN1656092A (enExample)
AR (1) AR040403A1 (enExample)
AT (1) ATE413399T1 (enExample)
AU (1) AU2003226757A1 (enExample)
BR (1) BR0308780A (enExample)
CA (1) CA2480106A1 (enExample)
CY (1) CY1108652T1 (enExample)
DE (1) DE60324535D1 (enExample)
DK (1) DK1487828T3 (enExample)
ES (1) ES2315519T3 (enExample)
IL (1) IL164047A0 (enExample)
IS (1) IS7444A (enExample)
MX (1) MXPA04009459A (enExample)
NO (1) NO20044448L (enExample)
PT (1) PT1487828E (enExample)
RU (1) RU2004127928A (enExample)
SI (1) SI1487828T1 (enExample)
TW (1) TW200400035A (enExample)
WO (1) WO2003082861A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1615878B1 (en) 2003-01-14 2012-04-04 Cytokinetics, Inc. Compounds, compositions and methods of treatment for heart failure
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
RS53600B1 (sr) 2004-06-17 2015-02-27 Cytokinetics, Inc. Jedinjenja, preparati i metode
AU2005261740A1 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
PL1801108T3 (pl) 2004-09-08 2013-04-30 Mitsubishi Tanabe Pharma Corp Związki morfolinowe do leczenia stanów zapalnych
CN101084216B (zh) 2004-10-20 2011-09-14 加利福尼亚大学董事会 可溶性环氧化物水解酶的改进抑制剂
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
CA3187052A1 (en) * 2020-07-29 2022-02-03 Eddy Sotelo Perez Functionalized isonitriles and products, preparation and uses thereof
CA3190593A1 (en) * 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
AU694226B2 (en) 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
EP0772611A1 (de) 1994-07-20 1997-05-14 Byk Gulden Lomberg Chemische Fabrik GmbH Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
AU1122399A (en) 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
HK1038749A1 (zh) 1998-09-30 2002-03-28 纽罗根公司 2-哌嗪烷基氨苯并吡咯衍生物:多巴胺受体亚型特异配体
BR0114323A (pt) 2000-09-29 2003-07-01 Glaxo Group Ltd Composto ou um seu sal ou solvato farmaceuticamente aceitável, composição farmacêutica, uso do composto ou de um seu sal ou solvato farmaceuticamente aceitável, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar o composto
BR0114321A (pt) * 2000-09-29 2003-07-01 Glaxo Group Ltd Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto

Also Published As

Publication number Publication date
DE60324535D1 (de) 2008-12-18
CA2480106A1 (en) 2003-10-09
WO2003082861A3 (en) 2004-03-11
SI1487828T1 (sl) 2009-04-30
IS7444A (is) 2004-09-13
KR20040093488A (ko) 2004-11-05
BR0308780A (pt) 2004-12-28
IL164047A0 (en) 2005-12-18
ATE413399T1 (de) 2008-11-15
TW200400035A (en) 2004-01-01
MXPA04009459A (es) 2005-01-25
PT1487828E (pt) 2009-01-06
NO20044448L (no) 2004-10-26
US20060063765A1 (en) 2006-03-23
US7622464B2 (en) 2009-11-24
RU2004127928A (ru) 2005-06-27
CY1108652T1 (el) 2014-08-13
CN1656092A (zh) 2005-08-17
WO2003082861A2 (en) 2003-10-09
JP2005526815A (ja) 2005-09-08
AU2003226757A1 (en) 2003-10-13
DK1487828T3 (da) 2009-02-02
EP1487828B1 (en) 2008-11-05
AR040403A1 (es) 2005-04-06
EP1487828A2 (en) 2004-12-22
ES2315519T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
JP4465195B2 (ja) 新規化合物
JP5089846B2 (ja) 炎症性疾患を処置するためのモルホリン−アセトアミド誘導体
JP6017313B2 (ja) 化合物および方法
HUP0303107A2 (hu) Gyulladásos betegségek kezelésére alkalmazható vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
US8404672B2 (en) Substituted heterocyclic compounds
JP2013517281A (ja) 化合物及び方法
AU1039300A (en) 4,5-dihydro-isoxazole derivatives and their pharmaceutical use
JPWO2016153023A1 (ja) 新規オキサジアゾール誘導体及びこれを含有する医薬
CN104024250A (zh) 作为痕量胺相关受体(taar)的杂环衍生物
JP5735634B2 (ja) スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
JP2005526807A (ja) 炎症性症状の治療においてｃｃｒ−３アンタゴニストとして使用するための、アリールアルキルウレア基により２位が置換されたモルホリン誘導体
JP2004534804A (ja) ピロリジン・オキサジアゾール−及びチアジアゾール誘導体
JP2005527564A (ja) 抗炎症性モルホリン−アセトアミド誘導体
AU2014246609A1 (en) Compounds and methods
WO2003099798A1 (en) Morpholinylmethylureas ccr-3 receptor antagonist

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091211

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100222

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130226

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4465195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130226

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140226

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term